Sydney Crackower, M.D.

Helping people lose weight for over 50 years

Semaglutide and Tirzepatide, groundbreaking medications, redefine weight loss by activating specific hormone receptors. These innovations offer effective solutions for achieving and maintaining a healthy weight, transforming the landscape of personalized weight management.
Call to Schedule appointment now

News Release

FDA-Approved Weight Loss Management Programs

40 years experience

Your Premier Healthcare Destination

Sydney Crackower, MD is a board-certified family medicine physician who has been providing expert medical care to the families of Lafayette, Louisiana, for more than 40 years. Each patient that comes to the office, including children, adults, and elderly, receives personalized care and attention from Dr. Crackower and his staff, building on trust and the patient-doctor relationship.

Dr. Crackower is trained to meet the diverse health needs of people of all ages from child to adulthood. He specializes in the management of chronic health conditions such as high blood pressure and diabetes, as well as providing expert care for patients suffering from chronic pain, depression, and anxiety.

Dr. Crackower is qualified to address the various medical requirements of individuals of all ages, from young children to adults.
In addition to offering patients with chronic pain, depression, and anxiety professional care, he specializes in the management of long-term health issues including diabetes and high blood pressure. While Dr. Crackower prioritizes patient well-being, people who are having trouble losing weight can take advantage of his medical weight reduction services.

Need a Doctor for Check-up?

Looking to embark on a weight loss journey? Our clinic specializes in top-notch services tailored for you and your family’s wellness.


FDA-Approved Injection For Weight Loss

Semaglutide For Weight Management

The U.S. Food and Drug Administration has granted approval for Semaglutide injection (2.4 mg once weekly) for chronic weight management in adults dealing with obesity or overweight, along with at least one weight-related condition. This under-the-skin injection marks a significant milestone as the first FDA-approved drug for chronic weight management in adults with general obesity or overweight since 2014. Semaglutide is intended for individuals with a body mass index (BMI) of 27 kg/m2 or greater and at least one weight-related ailment, or for those with a BMI of 30 kg/m2 or greater. It is recommended for use alongside a reduced-calorie diet and increased physical activity.


Medications For Weight Loss – FDA-Approved

Tirzepatide Injection

INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ — Selected Tirzepatide injections have secured approval from the U.S. Food and Drug Administration (FDA), marking a pioneering advancement as the first obesity treatment activating both GIP and GLP-1 hormone receptors. Zepbound is prescribed for adults with obesity (BMI of 30 kg/m2 or greater) or overweight (BMI of 27 kg/m2 or greater) who have weight-related medical concerns. This treatment supports weight loss and maintenance, necessitating adherence to a reduced-calorie diet and increased physical activity.

Our Testimonials

What clients Say?